234 related articles for article (PubMed ID: 34320420)
1. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
Kim RY; Li Y; Marmarelis ME; Vachani A
Lung Cancer; 2021 Sep; 159():107-110. PubMed ID: 34320420
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
McNamee N; Harvey C; Gray L; Khoo T; Lingam L; Zhang B; Nindra U; Yip PY; Pal A; Clay T; Arulananda S; Itchins M; Pavlakis N; Kao S; Bowyer S; Chin V; Warburton L; Pires da Silva I; John T; Solomon B; Alexander M; Nagrial A
J Thorac Oncol; 2024 Apr; 19(4):636-642. PubMed ID: 38036250
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
Parikh K; Hendriks LEL; Bironzo P; Remon J
Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
[TBL] [Abstract][Full Text] [Related]
9. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
Mutlu H; Gündüz S; Karaca H; Büyükçelik A; Cihan YB; Erden A; Akca Z; Coşkun HS
Med Oncol; 2014 Aug; 31(8):74. PubMed ID: 24958517
[TBL] [Abstract][Full Text] [Related]
10. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
[TBL] [Abstract][Full Text] [Related]
13. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
[TBL] [Abstract][Full Text] [Related]
14. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
[TBL] [Abstract][Full Text] [Related]
18. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V; Wegner RE; Brooks ED; Miccio JA; Kann BH; Finley GG; Raj MS; Grover S; Mohindra P; Simone CB
Clin Lung Cancer; 2019 Jul; 20(4):263-269. PubMed ID: 30992187
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Danese MD; Daumont M; Nwokeji E; Gleeson M; Penrod JR; Lubeck D
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1568. PubMed ID: 34698447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]